BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28584294)

  • 1. Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver.
    Fujisawa K; Takami T; Matsuzaki A; Matsumoto T; Yamamoto N; Terai S; Sakaida I
    Sci Rep; 2017 Jun; 7(1):2749. PubMed ID: 28584294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation.
    Kuwashiro S; Terai S; Oishi T; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
    Cell Tissue Res; 2011 Apr; 344(1):125-34. PubMed ID: 21327395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Savic D; Hodson L; Neubauer S; Pavlides M
    Nutrients; 2020 Jul; 12(8):. PubMed ID: 32708036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction.
    Jun DW; Cho WK; Jun JH; Kwon HJ; Jang KS; Kim HJ; Jeon HJ; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS; Hahm JS; Lee MH
    Liver Int; 2011 Oct; 31(9):1315-24. PubMed ID: 22093454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavangenol (pine bark extract) and its major component procyanidin B1 enhance fatty acid oxidation in fat-loaded models.
    Shimada T; Tokuhara D; Tsubata M; Kamiya T; Kamiya-Sameshima M; Nagamine R; Takagaki K; Sai Y; Miyamoto K; Aburada M
    Eur J Pharmacol; 2012 Feb; 677(1-3):147-53. PubMed ID: 22227333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Treatment with L-Carnitine and Nicotinamide Riboside Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis.
    Salic K; Gart E; Seidel F; Verschuren L; Caspers M; van Duyvenvoorde W; Wong KE; Keijer J; Bobeldijk-Pastorova I; Wielinga PY; Kleemann R
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medaka as a model for human nonalcoholic steatohepatitis.
    Matsumoto T; Terai S; Oishi T; Kuwashiro S; Fujisawa K; Yamamoto N; Fujita Y; Hamamoto Y; Furutani-Seiki M; Nishina H; Sakaida I
    Dis Model Mech; 2010; 3(7-8):431-40. PubMed ID: 20371730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice.
    Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P
    Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
    Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
    Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal variations in photoperiod affect hepatic metabolism of medaka (Oryzias latipes).
    Fujisawa K; Takami T; Shintani H; Sasai N; Matsumoto T; Yamamoto N; Sakaida I
    FEBS Open Bio; 2021 Apr; 11(4):1029-1040. PubMed ID: 33475250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfluorooctanoic acid induces peroxisomal fatty acid oxidation and cytokine expression in the liver of male Japanese medaka (Oryzias latipes).
    Yang JH
    Chemosphere; 2010 Sep; 81(4):548-52. PubMed ID: 20594573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation in the abcb7 gene causes abnormal iron and fatty acid metabolism in developing medaka fish.
    Miyake A; Higashijima S; Kobayashi D; Narita T; Jindo T; Setiamarga DH; Ohisa S; Orihara N; Hibiya K; Konno S; Sakaguchi S; Horie K; Imai Y; Naruse K; Kudo A; Takeda H
    Dev Growth Differ; 2008 Dec; 50(9):703-16. PubMed ID: 19046159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats.
    Ciapaite J; van den Broek NM; Te Brinke H; Nicolay K; Jeneson JA; Houten SM; Prompers JJ
    Biochim Biophys Acta; 2011; 1811(7-8):441-51. PubMed ID: 21621638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development.
    Xu Y; Han J; Dong J; Fan X; Cai Y; Li J; Wang T; Zhou J; Shang J
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis.
    Terashima Y; Nishiumi S; Minami A; Kawano Y; Hoshi N; Azuma T; Yoshida M
    Arch Biochem Biophys; 2014 Aug; 555-556():55-65. PubMed ID: 24857839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.